Can You Take Lion’s Mane With Blood Thinners?

No clinical trials have directly tested lion’s mane mushroom alongside blood-thinning medications, so there is no definitive safety verdict. What the lab evidence does show is a mixed picture: one compound in lion’s mane, called hericenone B, can inhibit a specific type of platelet clumping in test-tube studies, which raises a theoretical concern about increased bleeding risk. At the same time, a separate in vitro study found that lion’s mane extracts did not alter standard coagulation measures like prothrombin time or INR. The gap between those lab findings and what actually happens inside a person taking warfarin or aspirin is wide, and until human interaction studies fill it, caution is reasonable.

What Hericenone B Does to Platelets

The compound generating the most concern is hericenone B, found in the fruiting bodies of lion’s mane. In a 2010 study, researchers isolated hericenone B and tested it against several triggers of platelet aggregation. It selectively blocked collagen-induced platelet clumping but had no effect on aggregation triggered by ADP, thrombin, adrenaline, or a thromboxane A₂ analogue. The researchers concluded that hericenone B interferes with a specific signaling pathway between a collagen receptor on platelets (integrin α2/β1) and the release of arachidonic acid.¹ A separate review confirmed this antiplatelet activity, noting that hericenone B prevented platelet adhesion and thrombosis through inhibition of platelet aggregation.²

That selectivity matters. Hericenone B is not a broad-spectrum antiplatelet agent. It targets one arm of the platelet activation cascade while leaving the others untouched. By comparison, aspirin works by permanently disabling cyclooxygenase, which affects thromboxane-driven aggregation. Prescription antiplatelet drugs like clopidogrel block ADP receptors. Hericenone B’s mechanism does not overlap neatly with either of those. That said, when you are already on a medication designed to reduce clotting, even a modest additional reduction through a different pathway could, in theory, tip the balance toward excessive bleeding.

Why the Coagulation Studies Are Somewhat Reassuring

A 2019 in vitro study tested hot water extracts of eight edible mushroom species, lion’s mane among them, for both antiplatelet and anticoagulant activity. None of the mushroom extracts altered prothrombin time, prothrombin ratio, or International Normalized Ratio (INR).³ Those three measures are exactly what your doctor monitors if you take warfarin. The fact that lion’s mane extract left them unchanged in the lab suggests the mushroom does not interfere with the coagulation cascade in the same way warfarin does.

There is an important caveat, though. That study used hot water extracts, which pull out polysaccharides efficiently but may not capture the full spectrum of fat-soluble compounds like hericenones. The study also noted that other mushroom species in the screening showed stronger antiplatelet effects than lion’s mane did. So lion’s mane was not flagged as a standout risk even in a study specifically looking for platelet and coagulation effects. But again, this was lab glassware, not a person’s bloodstream, and the extract preparation method influences which compounds end up in the test solution.

Antiplatelet Versus Anticoagulant Effects

The term “blood thinner” gets applied to two very different categories of drugs, and the distinction is relevant when thinking about lion’s mane. Antiplatelet medications like aspirin and clopidogrel prevent platelets from sticking together. Anticoagulants like warfarin, heparin, and the newer direct oral anticoagulants (apixaban, rivarelbaxaban) interfere with clotting factors in the coagulation cascade. These are separate systems, even though both contribute to clot formation.

The concern with lion’s mane primarily sits on the antiplatelet side of the ledger. Hericenone B’s demonstrated activity is against platelet aggregation, not against clotting factors. The coagulation study mentioned above found no effect on the clotting-factor pathway. So if you are on warfarin specifically, the theoretical risk from lion’s mane looks smaller than if you are on an antiplatelet drug, because the mechanisms overlap less. But “smaller theoretical risk” is not the same as “no risk.” Nobody has confirmed this in people, and the body is more complicated than a test tube.

If you are on a combination of an antiplatelet and an anticoagulant, which some patients are after stent placement or certain cardiac events, any additional substance with platelet-modifying potential deserves extra scrutiny. Combination therapy already raises bleeding risk substantially, and the margin for adding anything that nudges platelet function is narrower.

How Much Hericenone B Are You Actually Getting?

This is arguably the biggest unknown in the whole question. The lab studies that demonstrated antiplatelet activity used isolated hericenone B at controlled concentrations. A commercial lion’s mane supplement is something entirely different. Lion’s mane products vary enormously in their composition depending on whether they are made from the fruiting body, the mycelium, or a blend of both. Hericenones are primarily found in the fruiting body. Mycelium-based products tend to be richer in a different class of compounds called erinacines and often contain a significant proportion of the grain substrate the mycelium was grown on.

Even among fruiting body products, the extraction method matters. Hot water extraction pulls out polysaccharides but may leave behind many of the less water-soluble hericenones. Ethanol or dual-extraction methods capture a broader range of compounds. A capsule of dried, powdered mushroom that has not been extracted at all will deliver a different chemical profile than either type of extract. None of these products are required to disclose their hericenone B content on the label, and very few do. So even if we knew exactly what dose of hericenone B would meaningfully affect platelet function in a living person, you would have no reliable way to know how much you are consuming from a typical supplement.

This uncertainty cuts both ways. It means the risk might be negligible because many products contain very little of the relevant compound. But it also means you cannot confidently say a product is safe just because lion’s mane in general looks low-risk. A concentrated fruiting body extract processed with ethanol could deliver a meaningfully different dose of hericenones than a budget mycelium powder.

What About Surgery and Procedures?

Even people not taking blood thinners are sometimes advised to stop supplements with antiplatelet potential before surgery. The concern is the same as with garlic, ginkgo, or fish oil: if a compound reduces platelet function even modestly, stacking that on top of the anticoagulation protocols used during and after surgery could increase bleeding. Many surgeons and anesthesiologists recommend discontinuing herbal and mushroom supplements at least one to two weeks before a planned procedure.

If you are already on a blood thinner and facing surgery, your care team will have a protocol for managing your medication. It is worth mentioning lion’s mane (and any other supplements) at the pre-surgical consultation so they can factor it in. The risk from any single supplement is probably small, but surgeons rightly prefer to eliminate as many unknowns as possible when bleeding risk is already elevated.

Gastrointestinal Considerations for People on Blood Thinners

People on anticoagulants or antiplatelet drugs already face a higher risk of gastrointestinal bleeding, which is one of the most common complications of long-term blood thinner use. Here, lion’s mane presents an interesting wrinkle. Animal research has shown that lion’s mane extracts protect the stomach lining against injury. In one study, an aqueous extract significantly reduced ulcer area in rats exposed to ethanol, preserved antioxidant enzymes in stomach tissue, and showed protective changes in protein markers associated with cell damage and survival.⁴ A separate study found that lion’s mane polysaccharides reduced both ethanol-induced gastric mucosal lesions and ulcers caused by pylorus ligation, through a combination of anti-inflammatory activity, antioxidant support, and increased release of protective factors in the stomach.⁵

These are animal studies and cannot be directly applied to clinical practice. But the gastroprotective findings at least suggest that lion’s mane is unlikely to irritate the stomach lining the way some supplements (or even aspirin itself) can. For someone on blood thinners who is worried about GI side effects from adding yet another pill to their routine, this is modestly encouraging. It does not, however, offset the antiplatelet concern, which operates through an entirely different mechanism.

The Broader Chemical Picture

Hericenone B gets the most attention in the blood-thinner discussion, but lion’s mane contains a complex array of bioactive compounds. Reviews of the mushroom’s chemistry have catalogued polysaccharides, erinacines, hericerins, hericenones (plural, as there are several variants), resorcinols, steroids, and various terpenes, with reported properties spanning neuroprotective, anti-inflammatory, antidiabetic, antihypertensive, and cardioprotective effects.⁶ Some of those properties, particularly the antihypertensive and lipid-lowering activities, could interact with cardiovascular medications in ways that have nothing to do with platelet function. If you are on blood thinners, you are likely managing a cardiovascular condition, and your medication regimen may include statins, ACE inhibitors, or beta-blockers alongside the anticoagulant. The potential for interaction is not limited to the clotting pathway alone.

None of these interactions have been studied in clinical trials either. But the sheer range of bioactive compounds in lion’s mane is a reminder that evaluating one compound in isolation, as the hericenone B platelet study did, gives you a fragment of the picture. A whole mushroom extract delivers dozens of compounds simultaneously, and their combined effect in a person taking multiple medications is genuinely unknown.

Practical Steps If You Want to Try Lion’s Mane While on Blood Thinners

The honest answer is that the evidence is too thin to give a confident yes or no. The theoretical risk exists, the severity of that risk is unclear, and no human study has tested the combination. Given those realities, a few practical steps can help you manage the uncertainty:

Talk to your prescriber first. This is not a generic disclaimer. Your doctor can assess your specific bleeding risk based on your medication, dose, kidney function, and history. Someone on a low-dose aspirin for primary prevention faces a very different risk calculus than someone on dual antiplatelet therapy after a heart attack.
Monitor for changes. If your doctor agrees to a trial, watch for signs of increased bleeding: unusual bruising, prolonged bleeding from minor cuts, blood in urine or stool, or heavier-than-normal menstrual flow. If you are on warfarin, your INR checks will serve as an objective monitor, though lion’s mane did not alter INR in the in vitro study mentioned earlier.
Start with a low dose. If you and your doctor decide the risk is acceptable, beginning with a smaller dose and increasing gradually gives you a chance to observe any effects before reaching typical supplement doses.
Consider the product type. A mycelium-on-grain product contains less of the fruiting body hericenones associated with antiplatelet activity. If your interest in lion’s mane is primarily for the nerve-growth-factor-related benefits linked to erinacines (found in mycelium), a mycelium product may carry a different risk profile. That said, this distinction has not been tested in the context of blood thinner interactions.
Discontinue before procedures. Stop lion’s mane at least two weeks before any scheduled surgery or invasive procedure, consistent with standard guidance for supplements that may affect bleeding.

Why the Research Gap Persists

You might wonder why nobody has just run the study. The answer is a combination of economics and regulatory structure. Lion’s mane is a natural product that cannot be patented, so there is limited financial incentive for a pharmaceutical company to fund a drug-interaction trial. Academic researchers, who might be interested, face the challenge that interaction studies require careful safety monitoring, ethical oversight for putting people on potentially risky combinations, and large enough sample sizes to detect relatively rare bleeding events. Most mushroom research funding comes from food science or agricultural departments, not clinical pharmacology programs.

Regulatory agencies in most countries treat mushroom supplements as foods or dietary supplements, not drugs, which means they do not require drug-interaction data before going to market. The result is a situation where millions of people take lion’s mane alongside prescription medications, and the safety data comes almost entirely from lab studies and animal models. This is not unique to lion’s mane; the same gap exists for most popular herbal and fungal supplements. The research tends to follow the popularity rather than lead it, so meaningful interaction data may eventually arrive, but it has not yet.

When Lion’s Mane Is Clearly Not Worth the Risk

A few situations tip the balance decisively toward avoiding lion’s mane until better evidence arrives. If you have a known bleeding disorder on top of blood thinner use, the margin for anything that could further impair clotting is essentially zero. If you are on triple antithrombotic therapy (two antiplatelet agents plus an anticoagulant), which is sometimes used short-term after coronary stenting in patients with atrial fibrillation, adding any supplement with antiplatelet signals is reckless. If you have experienced a previous serious bleeding event while on your current medication, your risk profile is already elevated and adding unknowns is inadvisable. And if you are about to have surgery or a dental extraction, the stakes of even minor additional bleeding risk increase sharply.

For someone on a single low-dose antiplatelet agent with no history of bleeding problems and no upcoming procedures, the theoretical risk from a typical lion’s mane supplement is probably very small. “Probably very small” is the most honest characterization the current evidence supports, and whether that is comfortable enough depends on your risk tolerance and your reasons for wanting to take lion’s mane in the first place. A conversation with whoever prescribed your blood thinner remains the most useful step you can take.